Natco Pharma Q1 net profit rises multi-fold to Rs 320 cr on higher revenue

Its consolidated revenue from operations during the quarter under review stood at Rs 884.6 crore compared to Rs 410.3 crore in the same period last fiscal, it added.

pharma
The company had posted a consolidated net profit of Rs 75 crore in the same period last fiscal, Natco Pharma said in a regulatory filing.
Press Trust of India New Delhi
2 min read Last Updated : Aug 09 2022 | 3:35 PM IST

Natco Pharma Ltd on Tuesday reported a multifold rise in consolidated net profit to Rs 320.4 crore for the first quarter ended June 30, on higher revenue from the pharmaceutical vertical.

The company had posted a consolidated net profit of Rs 75 crore in the same period last fiscal, Natco Pharma said in a regulatory filing.

Its consolidated revenue from operations during the quarter under review stood at Rs 884.6 crore compared to Rs 410.3 crore in the same period last fiscal, it added.

The pharmaceutical segment revenue increased to Rs 883.6 crore from Rs 409.7 crore in the first quarter of last year. This was inclusive of an income from the settlement of claims received by the company's arm Natco Pharma (Canada) Inc under a settlement agreement.

"During the quarter, export sales of Lenalidomide product to the US was a major contributor to the revenue and profitability of the business," Natco said, adding domestic formulations business remained steady.

Agrochemicals vertical registered revenue of Rs 1 crore, up from Rs 60 lakh in the year-ago quarter, the company said.

The total expenses in the first quarter were higher at Rs 533.1 crore against Rs 336.3 crore a year ago. There was a one-time cost associated with retirement schemes during the quarter and higher than usual R&D costs for product development, it added.

The company paid compensation totalling Rs 29.1 crore under the voluntary retirement scheme during the quarter ended June 30, 2022, Natco said.

The board of directors of the company has also approved an interim dividend of Rs 3.50 each per equity share of Rs 2 each for the financial year 2022-23, the filing said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Natco Pharma LtdPharmaceutical companies

First Published: Aug 09 2022 | 3:35 PM IST

Next Story